Junior Member
|
|
Join Date: Sep 2015
Posts: 32
|
|
Junior Member
Join Date: Sep 2015
Posts: 32
|
Quote:
Originally Posted by johnt
I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf
The conclusions:
"a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression."
John
|
Great Find!
|